0000899243-21-025303.txt : 20210622
0000899243-21-025303.hdr.sgml : 20210622
20210622171444
ACCESSION NUMBER: 0000899243-21-025303
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210621
FILED AS OF DATE: 20210622
DATE AS OF CHANGE: 20210622
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
CENTRAL INDEX KEY: 0001787092
STATE OF INCORPORATION: E9
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40489
FILM NUMBER: 211036209
BUSINESS ADDRESS:
STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC
STREET 2: 280 CONGRESS STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: (617) 951-5372
MAIL ADDRESS:
STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC
STREET 2: 280 CONGRESS STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Verve Therapeutics, Inc.
CENTRAL INDEX KEY: 0001840574
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 824800132
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: (978) 501-3026
MAIL ADDRESS:
STREET 1: 500 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-06-21
1
0001840574
Verve Therapeutics, Inc.
VERV
0001787092
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
C/O WELLINGTON MANAGEMENT COMPANY LLP
280 CONGRESS STREET
BOSTON
MA
02210
0
0
1
0
Common Stock
2021-06-21
4
C
0
1343081
A
1343081
D
Common Stock
2021-06-21
4
C
0
1152490
A
2495571
D
Series A-2 Preferred Stock
2021-06-21
4
C
0
12436264
D
Common Stock
1343081
0
D
Series B Preferred Stock
2021-06-21
4
C
0
10671482
D
Common Stock
1152490
0
D
The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date.
The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.
/s/ Wellington Biomedical Innovation Master Investors (Cayman) I L.P., By: Wellington Management Company LLP, as Investment Adviser, /s/ Peter McIsaac, Title: Authorized Person
2021-06-22